Corvus Pharmaceuticals, Inc.
As of Oct 22, 2026, Corvus Pharmaceuticals is in Stage 4, the downtrend phase, now in week 5 (since Sep 21, 2026). It closed at $10.65, 58.3% below its 52-week high and below its 200-day average, which is rising.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation an… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CRVS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CRVS among Biotechnology95th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …95 | CRVS | Stage 4 · wk 5 | 85 | −15.1% |
Corvus Pharmaceuticals: quick answers
What stage is Corvus Pharmaceuticals in?
As of Oct 22, 2026, Corvus Pharmaceuticals (CRVS) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 21, 2026 and is in week 5. What the four stages mean
Is Corvus Pharmaceuticals in an uptrend?
No. Corvus Pharmaceuticals is in a Stage 4 downtrend. It trades 25.7% below its 200-day average, which is rising.
How far is Corvus Pharmaceuticals from its 52-week high?
Corvus Pharmaceuticals closed at $10.65 on Oct 22, 2026, 58.3% below its 52-week high of $25.52. Its 52-week low is $6.50.
How has Corvus Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Corvus Pharmaceuticals is up 47.9% over the past year and up 45.5% so far in 2026.
Which sector and industry is Corvus Pharmaceuticals in?
Corvus Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.